VIVUS, Inc. to Present at Three Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., June 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that VIVUS management will present an overview of the company at three investment conferences during the month of June.

The conference presentation schedule is as follows:

A live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company’s lead product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of erectile dysfunction, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

SOURCE VIVUS, Inc.